hs-10365
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 9, 2021 (NCT05207787)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase receptor RETINHIBITOR
inhibitor - RET
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06823258 | Phase 1 | Feb 28, 2025 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT06147570 | Phase 2 | Sep 25, 2023 | Jiangsu Hansoh Pharmaceutical Co., Ltd., Jiao Tong University |
| NCT05207787 | Phase 1 | Nov 9, 2021 | Jiangsu Hansoh Pharmaceutical Co., Ltd., Jiao Tong University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | For profit | 3 | 3 | 2 | 2021 |
| Jiao Tong University | Academic/Hospital | 2 | 0 | 2 | 2021 |
2 organizations
Page 1 / 1